腹腔镜胃分隔胃空肠吻合术联合新辅助化疗后微创胃切除术治疗可切除胃癌伴胃出口梗阻的安全性与可行性
本研究回顾性分析54例可切除胃癌伴症状性胃出口梗阻患者,其中26例接受腹腔镜胃分隔胃空肠吻合术联合新辅助化疗后微创胃切除术,28例直接行微创胃切除术。结果显示联合策略安全可行,胃出口梗阻评分显著改善,新辅助化疗中位相对剂量强度达88.2%,复发累积发生率显著低于直接手术组。
要点
- 腹腔镜胃分隔胃空肠吻合术联合新辅助化疗可改善胃出口梗阻评分并维持化疗剂量强度
- 联合策略未增加术后并发症或延长住院时间,安全可行
- 新辅助化疗组复发累积发生率显著低于直接手术组,尤其低BMI和进展期患者可能获益
核心结论
- 腹腔镜胃分隔胃空肠吻合术联合新辅助化疗后微创胃切除术是晚期胃癌伴症状性胃出口梗阻安全可行的治疗策略。
研究设计与样本
- 单中心回顾性研究,纳入2007至2020年间经微创途径实现R0切除的54例患者,新辅助化疗组26例,直接手术组28例。
主要发现
- 胃分隔胃空肠吻合术后胃出口梗阻评分显著改善(p < 0.001)。
- 新辅助化疗中位相对剂量强度为88.2%。
- 两组术后并发症、术后住院时间和辅助化疗实施无差异。
- 新辅助化疗组复发累积发生率显著低于直接手术组(p = 0.041)。
- 新辅助化疗组复发和血行转移显著低于直接手术组(p = 0.031和0.041)。
临床怎么用
- 对于可切除胃癌伴症状性胃出口梗阻患者,可考虑腹腔镜胃分隔胃空肠吻合术联合新辅助化疗后再行微创胃切除术。
局限性
- 本研究为单中心回顾性研究,样本量有限,结论需进一步前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Advanced gastric cancer with gastric outlet obstruction (GOO) causes malnutrition and medication adherence issues, leading to a poor prognosis. We developed a novel multimodal, less invasive treatment approach for gastric cancer patients with symptomatic GOO: laparoscopic stomach-partitioning gastrojejunostomy (LSPGJ) combined with neoadjuvant chemotherapy (NAC), followed by minimally invasive gastrectomy with reuse of gastrojejunostomy. This study is a retrospective analysis of the safety and feasibility of our treatment strategy. METHODS: In this single-institution retrospective study, we enrolled 54 patients (NAC group, n = 26; upfront gastrectomy group, n = 28) who achieved R0 resection through a minimally invasive approach between 2007 and 2020 and evaluated their short- and long-term outcomes. RESULTS: After LSPGJ, the Gastric Outlet Obstruction Scoring System score significantly improved (p < 0.001). The median relative dose intensity of NAC was 88.2%. Regarding short-term outcomes, there were no differences in postoperative complications, length of postsurgical hospital stay, and adjuvant chemotherapy administration. Although overall survival and relapse-free survival showed trends toward improvement in the NAC group, these differences were not statistically significant. The cumulative incidence curve for recurrence in the NAC group was significantly lower than that of the upfront gastrectomy group (p = 0.041). Recurrence and hematogenous metastasis were significantly lower in the NAC group (p = 0.031 and 0.041, respectively) than in the upfront gastrectomy group. A forest plot revealed that NAC yielded favorable outcomes, particularly for patients with a body mass index (BMI) < 18.5 kg/m2, cT4, or cN1. CONCLUSIONS: LSPGJ combined with NAC followed by minimally invasive gastrectomy was a safe and feasible treatment strategy for patients with advanced gastric cancer with symptomatic GOO. This procedure may contribute to the early recovery of oral intake and help maintain NAC dose intensity, potentially improving prognosis, particularly for patients with low BMI and advanced-stage disease.
引用
- Tanaka T, Suda K, Nakauchi M, et al. Safety and feasibility of laparoscopic stomach-partitioning gastrojejunostomy combined with neoadjuvant chemotherapy followed by minimally invasive gastrectomy for resectable gastric cancer with gastric outlet obstruction. Surg Endosc. 2024. PMID: 39623174. doi:10.1007/s00464-024-11427-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。